Immune Globulin Subcutaneous (Human), 20%

immune globulin subcutaneous (human), 20% · Baxalta (now part of Shire)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Immune Globulin Subcutaneous (Human), 20%, covering 2021-05-05 to 2021-05-05. Get the full timeline:

Most recent: Clinical Trial Update: Immune Globulin Subcutaenous (Human), 20% [Phase 2, Phase 3]